Bold Therapeutics' Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy

VANCOUVER, BC, April 16, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, has shared new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects...